Treatment of early onset schizophrenia: Recent trends, challenges and future considerations

Frontiers in Psychiatry

Volumn 3, Issue APR, 2012, Pages

  Vyas, Nora S ^a   Gogtay, Nitin ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Adolescent; Antipsychotic; Early intervention; MEG; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER; CLOZAPINE; HALOPERIDOL; MOLINDONE; OLANZAPINE; RISPERIDONE;

AGRANULOCYTOSIS; AKATHISIA; AKINESIA; ARTICLE; CHILD DEVELOPMENT; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; DEVELOPMENTAL STAGE; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EARLY DIAGNOSIS; EARLY ONSET SCHIZOPHRENIA; FAMILY ASSESSMENT; GROUP THERAPY; HUMAN; HYPERGLYCEMIA; HYPERSALIVATION; LIVER DISEASE; MANAGED CARE; MOTOR DYSFUNCTION; MYOCARDITIS; MYOCLONUS; ONSET AGE; PHARMACEUTICAL CARE; PSYCHOEDUCATION; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA; SEIZURE; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT PLANNING; WEIGHT GAIN;

EID: 84866906300     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2012.00029     Document Type: Article

References (74)

1. Asarnow, J. R., Tompson, M. C., and Goldstein, M. J. (1994). Childhood-onset schizophrenia: a followup study. Schizophr. Bull. 20, 599-617.
2. Banaschewski, T., and Brandeis, D. (2007). Annotation: what electrical brain activity tells us about brain function that other techniques cannot tell us - a child psychiatric perspective. J. Child Psychol. Psychiatry 48,415-435.
3. Bechdolf, A., Wagner, M., Ruhrmann, S., Harrigan, S., Putzfeld, V., Pukrop, R., Brockhaus-Dumke, A., Berning, J., Janssen, B., Decker, P., Bottlender, R., Maurer, K., Möller, H. J., Gaebel, W., Häfner, H., Maier, W., and Klosterkötter, J. (2012). Preventing progression to first-episode psychosis in early initial prodoromal states. Br. J. Psychiatry 200, 22-29.
4. Brewer, W. J., Wood, S. J., Phillips, L. J., Francey, S. M., Pantelis, C., Yung, A. R., Cornblatt, B., and McGorry, P. D. (2006). Generalized and specific cognitive performance in clinical high-risk cohorts: a review highlighting potential vulnerability markers for psychosis. Schizophr. Bull. 32, 538-555.
5. Brookes, M. J., Woolrich, M., Luck-hoo, H., Price, D., Hale, J. R., Stephenson, M. C., Barnes, G. R., Smith, S. M., and Morris, P. G. (2011). Investigating the electrophysiological basis of resting state networks using magnetoencephalography. Proc. Natl. Acad. Sci. U.S.A. 108, 16783-16788.
6. Cadenhead, K. S., Addington, J., Cannon, T., Cornblatt, B., McGlashan, T., Perkins, D., Seidman, L., Tsuang, M., Walker, E., Woods, S., and Heinssen, R. (2010). Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study Cohort. Early Interv. Psychiatry 4, 220-226.
7. Cannon, T. D., Cadenhead, K., Cornblatt, B., Woods, S. W., Addington, J., Walker, E., Seidman, L. J., Perkins, D., Tsuang, M., McGlashan, T., and Heinssen, R. (2008). Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 65, 28-37.
8. Caplan, R. (1994). Communication deficits in childhood schizophrenia spectrum disorders. Schizophr. Bull. 20, 671-683.
9. Childs, B., and Scriver, C. R. (1986). Age at onset and causes of disease. Perspect. Biol. Med. 29, 437-460.
10. Connor, D. F., Fletcher, K. E., and Wood, J. S. (2001). Neuroleptic-related dyskinesias in children and adolescents. J. Clin. Psychiatry 62, 967-974.
11. Eack, S. M., Greenwald, D. P., Hogarty, S. S, Cooley, S. J., DiBarry, A. L., Montrose, D. M., and Keshaven, M. S. (2009). Cognitive enhancement therapy for early course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr. Serv. 60, 1468-1476.
12. Findling, R. L., Schulz, S. C., Reed, A. D., and Blumer, J. L. (1998). The antipsychotics: a pediatric perspective. Pediatr. Clin. North Am. 45, 1205-1232.
13. Fleischhaker, C., Schulz, E., Tepper, K., Martin, M., Hennighausen, K., and Remschmidt, H. (2005). Long-term course of adolescent schizophrenia. Schizophr. Bull. 31, 769-780.
14. Ford, J. M., Krystal, J. H., and Math-alon,D. H. (2007). Neural synchrony in schizophrenia: from networks to new treatment. Schizophr. Bull. 33, 848-852.
15. Gogtay, N., and Rapoport, J. (2008). Clozapine use in children and adolescents. Expert Opin. Pharmacother. 9,459-465.
16. Gogtay, N., Sporn, A., Clasen, L. S., Greenstein, D., Giedd, J. N., Lenane, M., Gochman, P. A., Zijdenbos, A., and Rapoport, J. L. (2003). Structural brain MRI abnormalities in healthy siblings of patients with childhood-onset schizophrenia. Am. J. Psychiatry 160, 569-571.
17. Gogtay, N., Sporn, A., Clasen, L. S., Nugent, T. F. III, Greenstein, D., Nicolson, R., Giedd, J. N., Lenane, M., Gochman, P., Evans, A., and Rapoport, J. L. (2004). Comparison of progressive cortical gray matter loss in childhood-onset schizophrenia with that in childhood-onset atypical psychoses. Arch. Gen. Psychiatry 61, 17-22.
18. Gogtay, N., Vyas, N. S., Testa, R., Wood, S. J., and Pantelis, C. (2011). Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr. Bull. 37, 504-513.
19. Gornick, M. C., Addington, A. M., Sporn, A., Gogtay, N., Greenstein, D., Lenane, M., Gochman, P., Ordonez, A., Balkissoon, R., Vakkalanka, R., Weinberger, D. R., Rapoport, J. L., and Straub, R E. (2005). Dys-bindin (DTNBP1, 6p22.3) is associated with childhood-onset psychosis and endophenotypes measured by the Premorbid Adjustment Scale (PAS). J. Autism Dev. Disord. 35,831-838.
20. Greenstein, D., Lenroot, R., Clausen, L., Chavez, A., Vaituzis, A. C., Tran, L., Gogtay, N., and Rapoport, J. L. (2011). Cerebellar development in childhood onset schizophrenia and non-psychotic siblings. Psychiatry Res. 193,131-137.
21. Gross, G., Huber, G., Klosterkotter, J., and Linz, M. (1987). Bonner Skalar fur die Beurteilungvon Basis-Symptomen. Berlin: Springer, 1995.
22. Heaton, R. K., Gladsjo, J. A., Palmer, B. W., Kuck, J., Marcotte, T. D., and Jeste, D. V. (2001). Stability and course of neuropsychological deficits in schizophrenia. Arch. Gen. Psychiatry 58,24-32.
23. Heinrichs, R. W., and Zakzanis, K. K. (1998). Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 12, 426-445.
24. Hollis, C. (2000). Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity. Am. J. Psychiatry 157, 1652-1659.
25. Ikezawa, K., Ishii, R., Iwase, M., Kuri-moto, R., Canuet, L., Takahashi, H., Nakahachi, T., Azechi, M., Ohi, K., Fukumoto, M., Yasuda, Y., Iike, N., Takaya, M., Yamamori, H., Kazui, H., Hashimoto, R., Yoshimine, T., and Takeda, M. (2011). Decreased alpha event-related synchro nization in the left posterior temporal cortex in schizophrenia: a magnetoencephalography-beamformer study. Neurosci. Res. 71,235-243.
26. Jacobsen, I. K., and Rapoport, J. L. (1998). Childhood-onset schizophrenia: rare but worth studying. Biol. Psychiatry 46, 1418-1428.
27. Javitt, D. C., Spencer, K. M., Thaker, G. K., Winterer, G., and Hajós, M. (2008). Neurophysiological biomarkers for drug development in schizophrenia. Nat. Rev. Drug Discov. 7, 68-83.
28. Keefe, R. S. E., and Fenton, W. S. (2007). How should DSM-V criteria for schizophrenia include cognitive impairment? Schizophr. Bull. 33, 912-920.
29. Kennedy, E., Kumar, A., and Datta, S. S. (2007). Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst. Rev. 4, 1-44.
30. Kumra, S., Frazier, J. A., Jacobsen, L. K., McKenna, K., Gordon, C. T., Lenane, M. C., Hamburger, S. D., Smith, A. K., Albus, K. E., Alaghband-Rad, J., and Rapoport, J. L. (1996). Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch. Gen. Psychiatry 53, 1090-1097.
31. Kumra, S., Kranzler, H., Gerbino-Rosen, G., Kester, H. M., De Thomas, C., Kafantaris, V., Correll, C. U., and Kane, J. M. (2008). Clozapine and'high-dose' olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol. Psychiatry 63, 524-529.
32. Levkovitz, Y., Rabany, L., Harel, E. V., and Zangen, A. (2011). Deep transcranial magnetic stimulation add-on for treatment of negative symptoms and cognitive deficits of schizophrenia: a feasibility study. Int. J. Neuropsychopharmacol. 14, 991-996.
33. Madaan, V., Dvir, Y., and Wilson, D. R. (2008). Child and adolescent schizophrenia: pharmacological approaches. Expert Opin. Pharmacother. 9, 2053-2068.
34. Masi, G., andLiboni, F. (2011). Management of schizophrenia in children and adolescents: focus on pharma-cotherapy. Drugs 71,179-208.
35. Mattai, A., Miller, R., Weisinger, B., Greenstein, D., Bakalar, J., Tossell, J., David, C., Wassermann, E. M., Rapoport, J., and Gogtay, N. (2011). Tolerability of transcranial direct current stimulation in childhood-onset schizophrenia. Brain Stimul. 4, 275-280.
36. McClellan, J., Breiger, D., McCurry, C., and Hlastala, S. (2003). Premorbid functioning in early-onset psychotic disorders. J. Am. Acad. ChildAdolesc. Psychiatry 42, 666-672.
37. McClellan, J., and Werry, J. (2001). Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J. Am. Acad. Child Adolesc. Psychiatry 40, 4S-23S.
38. McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosen-heck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S., Davis, C. E., Severe, J., and Hsiao, J. K. (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 153, 600-610.
39. McGlashan, T. H., Miller, T. J., Woods, S. W., Hoffman, R. E., and Davidson, L. (2001)."Ascale for the assessment of prodromal symptoms and states," in Early Intervention in Psychotic Disorders, eds T. J. Miller, S. A. Menick, T. H. McGlashan, J. Liberger, and J. O. Jahannessen (Dordrecht: Kluwer Academic Publishers), 135-149.
40. McGorry, P. D., Yung, A., and Phillips, L. (2001). Ethics and early intervention in psychosis: keeping up the pace and staying in step. Schizophr. Res. 51, 17-29.
41. McGorry, P. D., and Killackey, E. J. (2002). Early intervention in psychosis: a new evidence based paradigm. Epidemiol. Psichiatr. Soc. 11, 237-247.
42. McGurk, S. R., Twamley, E. W., Sitzer, D. I., McHugo, G. J., and Mueser, K. T. (2007). A meta-analysis of cognitive remediation in schizophrenia. Am. J. Psychiatry 164, 1791-1802.
43. Micó, J. A., Rojas-Corrales, M. O., Gibert-Rahola, J., Parellada, M., Moreno, D., Fraguas, D., Graell, M., Gil, J., Irazusta, J., Castro-Fornieles, J., Soutullo, C., Arango, C., Otero, S., Navarro, A., Baeza, I., Martínez-Cengotitabengoa, M., and González-Pinto, A. (2011). Reduced antiox-idant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry 11, 26. doi:10.1186/1471-244X-11-26
44. Miller, T. J., McGlashan, T. H., Woods, S. W., Stein, K., Driesen, N., Corcoran, C. M., Hoffman, R., and Davidson, L. (1999). Symptom assessment in schizophrenic prodromal states. Psychiatr. Q. 70, 273-287.
45. Minzenberg, M. J., and Carter, C. S. (2012). Developing treatments for impaired cognition in schizophrenia. Trends Cogn. Sci. (Regul Ed.) 16, 35-62.
46. Mozes, T., Toren, P., Chernauzan, N., Mester, R., Yoran-Hegesh, R., Blu-mensohn, R., and Weizman, A. (1994). Clozapine treatment in very early onset schizophrenia. J. Am. Acad. Child Adolesc. Psychiatry 33, 65-70.
47. Nicolson, R., Lenane, M., Singaracharlu, S., Malaspina, D., Giedd, J. N., Hamburger, S. D., Gochman, P., Bed-well, J., Thaker, G. K., Fernandez, T., Wudarsky, M., Hommer, D. W., and Rapoport, J. L. (2000). Premorbid speech and language impairments in childhood-onset schizophrenia: association with risk factors. Am. J. Psychiatry 157, 794-800.
48. Nicolson, R., and Rapoport, J. L. (1999). Childhood-onset schizophrenia: rare but worth studying. Biol. Psychiatry 46, 1418-1428.
49. Pantelis, C., Velakoulis, D., McGorry, P. D., Wood, S. J., Suckling, J., Phillips, L. J., Yung, A. R., Bull-more, E. T., Brewer, W., Soulsby, B., Desmond, P., and McGuire, P. K. (2003). Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet 361,281-288.
50. Patterson, T. L., and Leewenkamp, O. R. (2008). Adjunctive psychosocial therapies for the treatment of schizophrenia. Schizophr. Res. 100, 108-119.
51. Petersen, L., Jeppesen, P., Thorup, A., Abel, M. B., Øhlenschlaeger, J., Christensen, T. Ø., Krarup, G., Jørgensen, P., and Nordentofy, M. (2005). A randomized multicentre trial of integrated versus standard treatment for patients with a first episode of psychotic illness. BMJ 331,602.
52. Phillips, L. J., Young, A. R., and McGorry, P. D. (2002). Identification of young people at risk of psychosis: validation of Personal Assessment and Crisis Evaluation Clinic intake criteria. Aust. N. Z. J. Psychiatry 34(Suppl.),S164-S169.
53. Pool, D., Bloom, W., Mielke, D. H., Roniger, J. J. Jr., and Gallant, G. M. (1976). A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Curr. Ther. Res. Clin. Exp. 19,99-104.
54. Rapoport, J. L., Giedd, J., Kumra, S., Jacobsen, L., Smith, A., Lee, P., Nelson, J., and Hamburger, S. (1997). Childhood-onset schizophrenia. Progressive ventricular change during adolescence. Arch. Gen. Psychiatry 54, 897-903.
55. Rapoport, J. L., and Gogtay, N. (2011). Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. Int. J. Dev. Neurosci. 29,251-258.
56. Realmuto, G. M., Erickson, W. D., Yellin, A. M., Hopwood, J. H., and Green-berg, L.M. (1984). Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am. J. Psychiatry 141,440-442.
57. Reite, M., Teale, P., and Rojas, D. C. (1999). Magnetoencephalography: applications in psychiatry. Biol. Psychiatry 45, 1553-1563.
58. Ruhrmann, S., Schultze-LutterRaimo, F., Salokangas, R. K. R., Heini-maa, M., Linszen, D., Dingemans, P., Birchwood, M., Patterson, P., Juckel, G., Heinz, A., Morrison, A., Lewis, S., von Reventlow, H. G., and Klosterkötter, J. (2010). Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European Prediction of Psychosis study. Arch. Gen. Psychiatry 67,241-251.
59. Sikich, L., Frazier, J. A., McClellan, J., Findling, R. L., Vitiello, B., Ritz, L., Ambler, D., Puglia, M., Mal-oney A. E., Michael, E., De Jong, S., Slifka, K., Noyes, N., Hlastala, S., Pierson, L., McNamara, N. K., Delporto-Bedoya, D., Anderson, R., Hamer, R. M., and Lieberman, J. A. (2008). Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am. J. Psychiatry 165, 1420-1431.
60. Spencer, E. K., Kafantaris, V., Padron-Gayol, M. V., Rosenberg, C. R., and Campbell, M. (1992). Haloperidol in schizophrenic children: early findings from a study in progress. Psychopharmacol. Bull. 28,183-186.
61. Sporn, A. L., Vermani, A., Greenstein, D. K., Bobb, A. J., Spencer, E. P., Clasen, L. S., Tossell, J. W., Stayer, C. C., Gochman, P. A., Lenane, M. C., Rapoport, J. L., and Gogtay, N. (2007). Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J. Am. Acad. Child Adolesc. Psychiatry 46, 1349-1356.
62. Tanaka, S., and Watanabe, K. (2009). Transcranial direct current stimulation: a new tool for human cognitive neuroscience. Brain Nerve 61,53-64.
63. Taurines, R., Thome, J., Duvigneau, J. C., Forbes-Robertson, S., Yang, L., Klampfl, K., Romanos, J., Müller, S., Gerlach, M., and Mehler-Wex, C. (2010). Expression analyses of the mitochondrial complex I75-kDa subunit in early onset schizophrenia and autism spectrum disorder: increased levels as a potential bio-marker for early onset schizophrenia. Eur. Child. Adolesc. Psychiatry 19,441-448.
64. Towbin, K. E., Dykens, E. M., and Pugliese, R. G. (1994). Clozapine for early developmental delays in childhood-onset schizophrenia: protocol and 15-month outcome. J. Am. Acad. Child. Adolesc. Psychiatry 33,651-657.
65. Vercammen, A., Rushby, J. A., Loo, C., Short, B., Weickert, C. S., and Weickert, T. W. (2011). Transcranial direct current stimulation influences probabilistic association learning in schizophrenia. Schizophr. Res. 131, 198-205.
66. Vyas, N. S., Hadjulis, M., Vourdas, A., Byrne, P., and Frangou, S. (2007). The Maudsley early onset schizophrenia study. Predictors of psychosocial outcome at 4-year follow-up. Eur. Child Adolesc. Psychiatry 12, 465-470.
67. Vyas, N. S., Kumra, S., and Puri, B. K. (2010). What insights can we gain from studying early-onset schizophrenia? The neurodevelopmental pathway and beyond. Expert Rev. Neurother. 10, 1243-1247.
68. Vyas, N. S., Patel, N. H., and Puri, B. K. (2011a). Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv. Psychiatry 5, 3-14.
69. Vyas, N. S., Patel, N. H., Nijran, K. S., Al-Nahhas, A., and Puri, B. K. (2011b). The use of PET imaging in studying cognition, genetics and pharma-cotherapeutic interventions in schizophrenia. Expert. Rev. Neurother. 11, 37-51.
70. Vyas, N. S., Shamsi, S. A., Malhotra, A. K., Aitchison, K. J., and Kumari, V. (2012). Can genetics inform the management of cognitive deficits in schizophrenia? J. Psychopharmacol. 26, 334-348.
71. Weinberger, D. R. (1987). Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44, 660-669.
72. Wiedemann, K. (2011). Biomarker in development of psychotrophic drugs. Dialogues Clin. Neurosci. 13, 225-234.
73. Yung, A. R., and McGorry, P. D. (1996). The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr. Bull. 22, 353-370.
74. Yung, A. R., Phillips, L. J., Yuen, H. P., and McGorry, P. D. (2004). Risk factors for psychosis in an ultra high-risk group: psychopathology and clinical features. Schizophr. Res. 67, 131-142.